Recursion Pharmaceuticals Inc [NASDAQ: RXRX] stock went on a downward path that fall over -0.41% on Friday, amounting to a one-week price increase of more than 4.77%.
Over the last 12 months, RXRX stock dropped by -28.55%. The one-year Recursion Pharmaceuticals Inc stock forecast points to a potential upside of 25.35. The average equity rating for RXRX stock is currently 2.50, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.10 billion, with 425.48 million shares outstanding and 332.97 million shares in the current float. Compared to the average trading volume of 24.54M shares, RXRX stock reached a trading volume of 16956150 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Recursion Pharmaceuticals Inc [RXRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RXRX shares is $6.47 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RXRX stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Recursion Pharmaceuticals Inc shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on July 03, 2025. While these analysts kept the previous recommendation, Morgan Stanley raised their target price to Equal-Weight. The new note on the price target was released on May 22, 2023, representing the official price target for Recursion Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $17, while Needham analysts kept a Buy rating on RXRX stock.
The Price to Book ratio for the last quarter was 2.27, with the Price to Cash per share for the same quarter was set at 1.22.
RXRX Stock Performance Analysis:
Recursion Pharmaceuticals Inc [RXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.77. With this latest performance, RXRX shares dropped by -15.26% in over the last four-week period, additionally sinking by -18.69% over the last 6 months – not to mention a drop of -28.55% in the past year of trading.
Insight into Recursion Pharmaceuticals Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Recursion Pharmaceuticals Inc [RXRX] shares currently have an operating margin of -1005.82% and a Gross Margin at -57.68%. Recursion Pharmaceuticals Inc’s Net Margin is presently recorded at -1004.91%.
Recursion Pharmaceuticals Inc (RXRX) Capital Structure & Debt Analysis
According to recent financial data for Recursion Pharmaceuticals Inc. ( RXRX), the Return on Equity (ROE) stands at -86.34%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -62.47%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Recursion Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -65.79%, showcasing its effectiveness in deploying capital for earnings.
Recursion Pharmaceuticals Inc (RXRX) Efficiency & Liquidity Metrics
Based on Recursion Pharmaceuticals Inc’s (RXRX) latest financial statements, the Debt-to-Equity Ratio is 0.10%, indicating its reliance on debt financing relative to shareholder equity.
Recursion Pharmaceuticals Inc (RXRX) Efficiency & Liquidity Metrics
RXRX Stock EPS
With the latest financial reports released by the company, Recursion Pharmaceuticals Inc posted -0.34/share EPS, while the average EPS was predicted by analysts to be reported at -0.33/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.01. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for RXRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Recursion Pharmaceuticals Inc go to 21.31%.
Recursion Pharmaceuticals Inc [RXRX] Institutonal Ownership Details
There are presently around $69.30%, or 72.74%% of RXRX stock, in the hands of institutional investors. The top three institutional holders of RXRX stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 28.14 million shares, which is approximately 11.6199%. BAILLIE GIFFORD & CO, holding 26.59 million shares of the stock with an approximate value of $$199.42 million in RXRX stocks shares; and BAILLIE GIFFORD & CO, currently with $$161.67 million in RXRX stock with ownership which is approximately 8.9004%.
